Corcept Therapeutics Relacorilant FDA Rejection Lawsuits
Analysis based on 100 articles · First reported Mar 31, 2026 · Last updated Apr 21, 2026
The market is significantly impacted by the class action lawsuits against Knight Therapeutics, as its stock price plummeted by over 50% following the United States — Food and Drug Administration's rejection of its drug candidate, relacorilant. This event highlights the risks associated with pharmaceutical companies' drug development and regulatory approval processes, leading to investor losses and legal actions by firms like Rosen Law Firm, Hagens Berman, Kahn Swick & Foti, The Schall Law Firm, and Pomerantz LLP.
Multiple law firms, including Rosen Law Firm, Hagens Berman, Kahn Swick & Foti, The Schall Law Firm, and Pomerantz LLP, have filed class action lawsuits against Knight Therapeutics. These lawsuits allege that Knight Therapeutics misled investors about the approval prospects of its drug candidate, relacorilant, for hypercortisolism. The United States — Food and Drug Administration issued a Complete Response Letter for relacorilant's New Drug Application, citing insufficient evidence of effectiveness, which contradicted Knight Therapeutics' public statements about the drug 'approaching approval.' This disclosure led to a dramatic 50.4% drop in Knight Therapeutics' stock price on December 31, 2025, erasing nearly $2.5 billion in market capitalization. Investors who purchased Knight Therapeutics common stock between October 31, 2024, and December 30, 2025, are encouraged to join these lawsuits, with an important lead plaintiff deadline of April 21, 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard